167 related articles for article (PubMed ID: 38111524)
1. Treatment patterns and clinical outcomes in 157 patients with extensive-stage small cell lung cancer: real-world evidence from a single-center retrospective study.
Zheng Y; Tan K; Wang A; Lu X; Dong H; Li J; Cui H
Front Oncol; 2023; 13():1287628. PubMed ID: 38111524
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
4. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
5. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
Zheng J; Deng Y; Huang B; Chen X
Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.
Valette CA; Filleron T; Debieuvre D; Lena H; Pérol M; Chouaid C; Simon G; Quantin X; Girard N
Respir Med Res; 2023 Nov; 84():101012. PubMed ID: 37307617
[TBL] [Abstract][Full Text] [Related]
9. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.
Mi S; Yang Y; Liu X; Tang S; Liang N; Sun J; Liu C; Ren Q; Lu J; Hu P; Zhang J
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38598001
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
[TBL] [Abstract][Full Text] [Related]
13. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
Liu X; Xing H; Liu B
Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis.
Chen CR; Qi WX; Liu T; Tong X
Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5857-5867. PubMed ID: 36066161
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T; Li Y; Zheng X
BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety comparison of PD-1 inhibitors
Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
19. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
Korde R; Veluswamy R; Allaire JC; Barnes G
Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis.
Chen CY; Chen WC; Hung CM; Wei YF
Immunotherapy; 2021 Oct; 13(14):1165-1177. PubMed ID: 34261336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
